An experimental obesity injection that no regulator anywhere in the world has approved is being sold to American consumers by clinics and medical spas staffed by licensed practitioners, and poison center data show the consequences are already arriving.
Eli Lilly, the drug developer, escalated its response on August 12, 2026, filing six new lawsuits against U.S. entities selling black-market versions of retatrutide. The defendants are Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co., a mix of compounding pharmacies, medical spas, and online sellers. The company said it has referred more than 200 individuals and entities to the FDA, the Justice Department, state attorneys general, law enforcement, and professional licensing boards, and has flagged more than 14,000 websites, advertisements, social media posts, and product listings across more than 100 countries.
